ScreenPoint Medical Reports the Acquisition of Biomediq, Bolstering its Breast Cancer Risk Evaluation Capabilities
Shots:
- ScreenPoint has acquired Biomediq, enhancing its breast cancer risk evaluation abilities by adding Breast AI platform, Transpara, that uses Mammographic Texture Risk biomarkers to analyze 2D & 3D mammograms & predict short & long-term risk
- ScreenPoint has launched Transpara 2.1, with advanced features like automated breast density evaluation (BIRADS & volumetric) & temporal comparison. Transpara 2.1, incl. Detection, Temporal Comparison & Density options, is CE-marked & FDA-cleared
- A 2023 Radiology study highlighted the efficacy of Transpara's Detection & Density tools with Biomediq's texture model, showing improved cancer risk prediction with Transpara-based lesion detection, volumetric density assessment & quantitative texture analysis
Ref: PRNewswire | Image: ScreenPoint Medical
Related News:- Boston Scientific Reports the Acquisition of Silk Road Medical
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
